An update on human papillomavirus vaccine uptake among 11-17 year old girls in the United States: National Health Interview Survey, 2010

Vaccine

Volumn 30, Issue 24, 2012, Pages 3534-3540

  Laz, Tabassum H ^a   Rahman, Mahbubur ^a   Berenson, Abbey B ^a  

^a UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

Adolescent; HPV vaccine; Human papillomavirus; National Health Interview Survey; Vaccination; Vaccine uptake

Indexed keywords

WART VIRUS VACCINE;

ADOLESCENT; ARTICLE; AWARENESS; CHILD; DRUG COST; DRUG SAFETY; DRUG UPTAKE; FEMALE; HEALTH SURVEY; HISPANIC; HUMAN; MAJOR CLINICAL STUDY; NATIONAL HEALTH INTERVIEW SURVEY; PAPILLOMAVIRUS INFECTION; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; UNITED STATES; VACCINATION;

ADOLESCENT; CHILD; DRUG UTILIZATION; ETHNIC GROUPS; FEMALE; HUMANS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; UNITED STATES; UTERINE CERVICAL NEOPLASMS; VACCINATION;

EID: 84861001629     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.03.067     Document Type: Article

References (41)

1. Bosch F.X., de Sanjoseó S.S. Chapter 1: Human papillomavirus and cervical cancer - burden and assessment of causality. J Natl Cancer Inst Monogr 2003, 31:3-13.
2. Garland S.M., Steben M., Sings H.L., James M., Lu S., Railkar R., et al. Natural history of genital warts: analysis of placebo arm of 2 randomized phase III trials of quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine. J Infect Dis 2009, 199:805-814.
3. Moscicki A., Schiffman M., Kjaer S., Villa LL Chapter 5: Updating the natural history of HPV and anogenital cancer. Vaccine 2006, 24S3:42-51.
4. Markowitz L.E., Dunne E.F., Saraiya M., Lawson H.W., Chesson H., Unger E.R. Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007, 56:1-24.
5. Centers for Disease Control and Prevention FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendation from the Advisory Committee on Immunization Practices (ACIP). MMWR 2010, 59:626-629.
6. Villa L.L., Costa R.L., Petta C.A., Andrade R.P., Paavonen J., Iversen O.E., et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus like particle vaccine through 5 year of follow-up. Br J Cancer 2006, 95:1459-1466.
7. Romanowski B., de Borba P.C., Naud P.S., Roteli-Martins C.M., De Carbalho N.S., Teixeira J.C., et al. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 ASO4-adjuvanted vaccine: analysis of a randomized placebo-controlled trial up to 6.4 years. Lancet 2009, 374:1975-1985.
8. Centers for Disease Control and Prevention Recommendations on the use of quadrivalent human papillomavirus vaccine in males - Advisory Committee on Immunization Practices (ACIP). MMWR 2011, 60:1705-1708.
9. Kahn J.A., Rosenthal S.L., Jin Y., Huang B., Namakydoust A., Zimet G.D. Rates of human papillomavirus vaccination, attitudes about vaccination, and human papillomavirus prevalence in young women. Obstet Gynecol 2008, 111:1103-1110.
10. Conroy K., Rosenthal S.L., Zimet G.D., Jin Y., Bernstein D.I., Glynn S., et al. Human papillomavirus vaccine uptake, predictors of vaccination, and self-reported barriers to vaccination. J Womens Health 2009, 18:1679-1686.
11. Gottlieb S.L., Brewer N.T., Sternberg M.R., Smith J.S., Ziarnowski K., Liddon N., et al. Human papillomavirus vaccine initiation in an area with elevated rates of cervical cancer. J Adolesc Health 2009, 45:430-437.
12. Rosenthal S.L., Rupp R., Zimet G.D., Meza H.M., Loza M.L., Short M.B., et al. Uptake of HPV vaccine: demographics, sexual history and values, parenting style, and vaccine attitude. J Adolesc Health 2008, 43:239-245.
13. Cook R.L., Zhang J., Mullins J., Kauf T., Brumback B., Steingraber H., et al. Factors associated with initiation and completion of human papillomavirus vaccine series among young women enrolled in Medicaid. J Adolesc Health 2010, 47:596-599.
14. Chao C., Velicer C., Slezak J.M., Jacobsen S.J. Correlates for human papillomavirus vaccination of adolescent girls and young women in a managed care organization. Am J Epidemiol 2010, 171:357-367.
15. Dempsey A., Cohn L., Dalton V., Ruffin M. Patient and clinic factors associated with adolescent human papillomavirus vaccine utilization within a university-based health system. Vaccine 2010, 28:989-995.
16. Brewer N.T., Gottlieb S.L., Reiter P.L., McRee A., Liddon N., Markowitz L.E., et al. Longitudinal predictors of human papillomavirus vaccine initiation among adolescent girls in a high-risk geographic area. Sex Transm Dis 2011, 38:197-204.
17. Guerry S.L., De Rosa C.J., Markowitz L.E., Walker S., Liddon N., Kerndt P.R., et al. Human papillomavirus vaccine initiation among adolescent girls in a high-risk communities. Vaccine 2011, 29:2235-2241.
18. Caskey R., Lindau S.T., Alexander G.C. Knowledge and early adoption of the HPV vaccine among girls and young women: results of a national survey. J Adolesc Health 2009, 45:453-462.
19. Pruitt S.L., Schootman M. Geographic disparity, area poverty, and human papillomavirus vaccination. Am J Prev Med 2010, 38:525-533.
20. Tylor L.D., Harriri S., Sternberg M., Dunne E.F., Markowitz L.E. Human papillomavirus vaccine coverage in the United States, National Health and Nutrition Examination Survey, 2007-2008. Prev Med 2011, 52:398-400.
21. Wong C.A., Berkowitz Z., Dorell C.G., Price R.A., Lee J., Saraiya M. Human papillomavirus vaccine uptake among 9- to 17-year-old girls: National Health Interview Survey, 2008. Cancer 2011, 117:5612-5620.
22. Centers for Disease Control and Prevention National, state, and local area vaccination coverage among adolescents aged 13-17 years - United States, 2008. MMWR 2009, 58:997-1001.
23. National Center for Health Statistics National Health Interview Survey (NHIS). Public use data release: NHIS Survey Description, available at: 2010 [retrieved 17.12.10]. ftp://ftp.cdc.gov/pub/Health_Statistics/NCHS/Dataset_Documentation/NHIS/2010/srvydesc.pdf.
24. Centers for Disease Control and Prevention. National and state vaccination coverage among adolescents aged 13 through 17 years - United States, 2010. MMWR 2011, 60:1117-2011.
25. Centers for Disease Control and Prevention. National, state, and local area vaccination coverage among adolescents aged 13-17 years - United States, 2009. MMWR 2010, 59:1018-1023.
26. Jain N., Singleton J.A., Montgomery M., Skalland B. Determining accurate vaccination coverage rates for adolescents: the National Immunization Survey-Teen 2006. Public Health Rep 2009, 124:642-651.
27. Montgomery M., Khare M., Wouhib A., Singleton J., Jain N. Assessment of bias in the National Immunization Survey-Teen: benchmarking to the National Health Interview Survey. Abstract presented at: American Association for Public Opinion Research Conference 2008.
28. Reiter P.L., Cates J.R., McRee A.L., Gottlieb S.L., Shafer A., Smith J.S., et al. Statewide HPV vaccine initiation among adolescent females in North Carolina. Sex Transm Dis 2010, 37:549-556.
29. Kahn J.A., Ding L., Huang B., Zimet G.D., Rosenthal S.L., Frazier A.L. Mothers' intention for their daughters and themselves to receive the human papillomavirus vaccine: a national study of nurses. Pediatrics 2009, 123:1439-1445.
30. Daley M.F., Crane L.A., Markowitz L.E., Black S.R., Beaty B.L., Barrow J., et al. Human papillomavirus vaccination practices: a survey of US physicians 18 months after licensure. Pediatrics 2010, 126:425-433.
31. Vadaparampil S.T., Kahn J.A., Salmon D., Lee J., Quinn G.P., Roetzheim R., et al. Missed clinical opportunities: provider recommendations for HPV vaccination for 11-12 year old girls are limited. Vaccine 2010, 29:8634-8641.
32. Merck & Co. A program to help improve patient compliance: 3 is key, available at: 2010 [retrieved 17.12.10]. http://www.merckvaccines.com/vaccines/gardasil/compliance_one.html.
33. Kreimer A.R., Rodriguez A.C., Hildesheim A., Herrero R., Porras C., Schiffman M., et al. Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. J Natl Cancer Inst 2011, 103:1-8.
34. Chou B., Krill L.S., Horton B.B., Barat C.E., Trimble C.L. Disparities in human papillomavirus vaccine completion among vaccine initiators. Obstet Gynecol 2011, 118:14-20.
35. Niccolai L.M., Mehta N.R., Hadler J.L. Racial/ethnic and poverty disparities in human papillomavirus vaccination completion. Am J Pev Med 2011, 41:428-433.
36. Centers for Disease Control and Prevention. Vaccines for Children: for parents, available at: 2010 [retrieved 17.12.10]. http://www.cdc.gov.proxy-hs.researchport.umd.edu/vaccines/programs/vfc/parents/default.html%23eligible.
37. Chao C., Velicer C., Slezak J.M., Jacobsen S.J. Correlates for completion of 3-dose regimen of HPV vaccine in female members of a managed care organization. Mayo Clin Proc 2009, 84:864-870.
38. Neubrand T.P., Breitkopf C.R., Rupp R., Breitkopf D., Rosenthal S.L. Factors associated with completion of the human papillomavirus vaccine series. Clin Pediatr 2009, 19:411-416.
39. McDougall J.A., Madeleine M.M., Daling J.R., Li C.I. Racial and ethnic disparities in cervical cancer incidence rates in the United States, 1992-2003. Cancer Causes Control 2007, 18:1175-1186.
40. National Cancer Institute SEER Stat Fact Sheets-Cancer of the Cervix Uteri, available at: 2010 [retrieved 17.12.10]. http://seer.cancer.gov/statfacts/html/cervix.html.
41. Watson F.M., Saraiya M., Benard V., Coughlin S.S., Flowers L., Cokkinides V., et al. Burden of cervical cancer in the United States, 1998-2003. Cancer 2008, 113:2855-2864.